Accuray(ARAY)
MADISON, WI
Biotechnology1 H-1B visas (FY2023)Focus: Directed Radiation Therapy
Accuray is a life sciences company focused on Directed Radiation Therapy.
Oncology
Funding Stage
PUBLIC
Open Jobs
22
Pipeline & Clinical Trials
CyberKnife Stereotactic Radiosurgery
Prostate CancerClinical Trials (1)
NCT00643994CyberKnife Radiosurgery for Organ-Confined Prostate Cancer: Homogenous Dose Distribution
N/ACyberKnife Stereotactic Radiosurgery - Low Risk
Prostate CancerClinical Trials (1)
NCT00643617CyberKnife Radiosurgery For Low & Intermediate Risk Prostate Cancer: Emulating HDR Brachytherapy Dosimetry
N/ACyberKnife Stereotactic Radiotherapy
Non-small Cell Lung CancerClinical Trials (1)
NCT00840749Randomized Study to Compare CyberKnife to Surgical Resection In Stage I Non-small Cell Lung Cancer
N/AStereotactic Post-operative Radiotherapy for Endometrial Cancer
Endometrial CancerClinical Trials (1)
NCT06360653a SIngle Center Study of Post-operative STEReotactic RAdiotherapY for Endometrial Cancer
N/Aradiosurgical hypophysectomy
Bone MetastasesClinical Trials (1)
NCT03377517Radiosurgical Hypophysectomy for Bone Metasteses Pain
N/ALaboratory Biomarker Analysis
Metastatic Malignant Neoplasm in the BrainClinical Trials (1)
NCT02716948SRS and Nivolumab in Treating Patients With Newly Diagnosed Melanoma Metastases in the Brain or Spine
Phase 1CyberKnife SBRT
Colorectal Liver MetastasesClinical Trials (1)
NCT01318447CyberKnife® for Hepatic Metastases From Colorectal Cancer
Phase 25Fluorouracile and Mitomycin-C
Locally Advanced Anal Canal CancerClinical Trials (1)
NCT02701088Study of SIB-IMRT in Combination With 5-FU and Mitomycin-C Among Patients With Locally Advanced Anal Canal Cancer: Efficacy, Safety and Quality of Life
Phase 2CyberKnife Stereotactic Radiosurgery
Non-small Cell Lung CancerClinical Trials (1)
NCT00643318CyberKnife Radiosurgical Treatment of Inoperable Early Stage Non-Small Cell Lung Cancer
Phase 2CyberKnife
Carcinoma, HepatocellularClinical Trials (1)
NCT01327521Transarterial Chemoembolization vs CyberKnife for Recurrent Hepatocellular Carcinoma
Phase 3Transarterial Chemoembolization
Recurrent Hepatocellular CarcinomaClinical Trials (1)
NCT01318200Transarterial Chemoembolization (TACE) vs. CyberKnife for Recurrent Hepatocellular Carcinoma (HCC)
Phase 3Open Jobs (22)
Clinical Sales Director
Remote
Yesterday
Field Service Engineer - Remote in Memphis, TN
Remote
6d ago
Data Science Intern
Madison, WI
2w ago
Business Intelligence Intern
Madison, WI
2w ago
Field Service Engineer Tokyo
Tokyo
Engineering3w ago
Field Service Engineer Nagoya
Remote
Engineering3w ago
Regional Sales Director - Western U.S.
Remote
Commercial3w ago
Senior Manager, Total Rewards & HR Systems
Madison, WI
Human Resources4w ago
Field Service Engineer - EIMEA – India – Coimbatore
Remote
Engineering1mo ago
Traffic/Ship Coordinator
Madison, WI
1mo ago
Regional Sales Director - Mid-Atlantic
Remote
Commercial1mo ago
Regional Sales Director - Midwest
Remote
Commercial1mo ago
Regional Sales Director - East Coast
Remote
Commercial1mo ago
Regional Sales Director
Remote
Commercial1mo ago
Regional Sales Director - South Central US
Remote
Commercial1mo ago
Manufacturing Test Engineer
Madison, WI
Manufacturing1mo ago
SEC Reporting Analyst
Madison, WI
1mo ago
Sales Manager ASEAN Region
Remote
Commercial2mo ago
Field Service Engineer Talent Community - General Interest
Remote
Engineering4mo ago
Operations and Production Talent Community - General Interest
Madison, WI
Manufacturing5mo ago
Supplier Quality Talent Community - General Interest Pipeline
Madison, WI
Human Resources5mo ago
Engineering Talent Community - General Interest Pipeline
Madison, WI
Engineering5mo ago
Interview Prep Quick Facts
Portfolio: 11 clinical trials
Top TAs: Oncology
H-1B (2023): 1 approval
Publications: 25 in PubMed
SEC Filings: 2 available
Open Roles: 22 active jobs
Financials (FY2025)
Revenue
$447M4%
R&D Spend
$50M(11%)14%
Net Income
-$16MCash
$69MHiring Trend
Actively Hiring
22
Open Roles
+4
Added
-1
Filled/Removed
Based on last 4 crawl cycles
Visa Sponsorship
Sponsors Work Visas
H-1B Petitions (FY2023)
1
Approved
0
Denied
100%
Rate
Source: USCIS H-1B Employer Data Hub